242 related articles for article (PubMed ID: 2211445)
1. In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients.
Rolston KV; LeBlanc B; Ho DH; Bodey GP
J Antimicrob Chemother; 1990 Jul; 26(1):39-44. PubMed ID: 2211445
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients.
Rolston KV; LeBlanc B; Gooch G; Ho DH; Bodey GP
J Antimicrob Chemother; 1989 Mar; 23(3):363-71. PubMed ID: 2732120
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of PD127,391, a new quinolone against bacterial isolates from cancer patients.
Rolston KV; Ho DH; LeBlanc B; Bodey GP
Chemotherapy; 1990; 36(5):365-72. PubMed ID: 2209169
[TBL] [Abstract][Full Text] [Related]
4. In-vitro activity of four new fluoroquinolones.
García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients.
Rolston KV; Ho DH; LeBlanc B; Gooch G; Bodey GP
Eur J Clin Microbiol Infect Dis; 1988 Oct; 7(5):684-6. PubMed ID: 3143585
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.
Rolston KV; Frisbee-Hume S; LeBlanc BM; Streeter H; Ho DH
Diagn Microbiol Infect Dis; 2002 Oct; 44(2):187-94. PubMed ID: 12458127
[TBL] [Abstract][Full Text] [Related]
7. Lomefloxacin, a new difluoroquinolone: in vitro activity against gram-positive and gram-negative bacteria.
Hoban D; Grabowski M; Koss J; Weselowski V
Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):77S-82S. PubMed ID: 2791502
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patients.
Rolston K; Ho DH; LeBlanc B; Bodey GP
Chemotherapy; 1988; 34(6):448-54. PubMed ID: 3149568
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.
Rolston KV; Nguyen H; Messer M; LeBlanc B; Ho DH; Bodey GP
Antimicrob Agents Chemother; 1990 Nov; 34(11):2263-6. PubMed ID: 2127348
[TBL] [Abstract][Full Text] [Related]
10. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
Dholakia N; Rolston KV; Ho DH; LeBlanc B; Bodey GP
Antimicrob Agents Chemother; 1994 Apr; 38(4):848-52. PubMed ID: 8031057
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.
Clement JJ; Tanaka SK; Alder J; Vojtko C; Beyer J; Hensey D; Ramer N; McDaniel D; Chu DT
Antimicrob Agents Chemother; 1994 May; 38(5):1071-8. PubMed ID: 8067740
[TBL] [Abstract][Full Text] [Related]
12. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients.
Rolston KV; Frisbee-Hume S; LeBlanc B; Streeter H; Ho DH
Diagn Microbiol Infect Dis; 2003 Oct; 47(2):441-9. PubMed ID: 14522520
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activity of lomefloxacin, a difluoro-quinolone.
Robbins MJ; Baskerville AJ; Sanghrajka M; Mumtaz G; Felmingham D; Ridgway GL; Grüneberg RN
Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):65S-76S. PubMed ID: 2791500
[TBL] [Abstract][Full Text] [Related]
14. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
McCarter YS; Mazens-Sullivan MF; Bartlett RC
Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates.
Ling TK; Liu EY; Cheng AF
Chemotherapy; 1999; 45(1):22-7. PubMed ID: 9876206
[TBL] [Abstract][Full Text] [Related]
16. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.
Cooper MA; Andrews JM; Ashby JP; Matthews RS; Wise R
J Antimicrob Chemother; 1990 Nov; 26(5):667-76. PubMed ID: 2079449
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
Barry AL; Fuchs PC
J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin.
Floyd-Reising SA; Kelley SG; Hindler JA; Young LS
Diagn Microbiol Infect Dis; 1987 Apr; 6(4):301-6. PubMed ID: 3472704
[TBL] [Abstract][Full Text] [Related]
19. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.
Fung-Tomc J; Minassian B; Kolek B; Washo T; Huczko E; Bonner D
J Antimicrob Chemother; 2000 Apr; 45(4):437-46. PubMed ID: 10747819
[TBL] [Abstract][Full Text] [Related]
20. In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
Tanaka M; Yamazaki E; Chiba M; Yoshihara K; Akasaka T; Takemura M; Sato K
Antimicrob Agents Chemother; 2002 Mar; 46(3):904-8. PubMed ID: 11850285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
